PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.
Information regarding PGx on FDA drug labels is derived from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels". Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.
Nelfinavir is a protease inhibitor which is used in combination with other medications to treat human immunodeficiency virus (HIV) infection by slowing the spread of the infection within the body. It is metabolized by cytochrome P-450 enzymes, mainly CYP3A and CYP2C19.
Excerpts from the Nelfinavir drug label:
"Nelfinavir is an inhibitor of the CYP3A enzyme. Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could prolong its therapeutic and adverse effects."
"Nelfinavir is metabolized by CYP3A and CYP2C19. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations."
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Nelfinavir drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
| Position ? | Drug ? | Relevance ? |
Strength of Evidence ? |
||
|---|---|---|---|---|---|
Download a summary of all Clinical Annotations available.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
|
Variant?
(build 132) |
Alternate Names ? | Drugs ? |
Alleles
?
(+ chr strand) |
Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|
| rs12333983 |
T > A
|
Not Available | ||||
| rs12721627 | CYP3A4*16, CYP3A4*16A, CYP3A4:185 Thr>Ser, CYP3A4:554C>G, CYP3A4:658 C>G, CYP3A4:T185S, CYP3A4:Thr185Ser, c.554C>G, g.151601C>G, g.20716C>G, g.37398936G>C, g.98581C>G, p.Thr185Ser |
G > C
|
Missense |
Thr185Ser
|
||
| rs12721634 | CYP3A4*14, CYP3A4:L15P, c.44T>C, g.136042T>C, g.37414504A>G, g.5148T>C, g.83013T>C, p.Leu15Pro |
A > G
|
Missense |
Leu15Pro
|
||
| rs15524 |
A > G
|
Not Available | ||||
| rs2242480 |
C > T
|
Not Available | ||||
| rs2246709 |
A > G
|
Not Available | ||||
| rs2740574 | 5'-flanking region -392A>G, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G, g.135607A>G, g.37414939C>T, g.4713G>A, g.82578G>A |
C > T
|
Not Available | |||
| rs35599367 |
G > A
|
Not Available | ||||
| rs4646457 |
A > C
|
Not Available | ||||
| rs4646458 |
T > G
|
Not Available | ||||
| rs4986907 | CYP3A4*15A, CYP3A4:589G>A, CYP3A4:Arg162Gln, CYP3A4:R162Q, c.485G>A, g.150267G>A, g.19382G>A, g.37400270C>T, g.97247G>A, p.Arg162Gln |
C > T
|
Missense |
Arg162Gln
|
||
| rs4986908 | CYP3A4*10, CYP3A4:624 G>C, CYP3A4:D174H, c.520G>C, g.150302G>C, g.19417G>C, g.37400235C>G, g.97282G>C, p.Asp174His |
C > G
C > T
|
Missense |
Asp174His
|
||
| rs4986909 | CYP3A4*13, CYP3A4:1351 C>T, CYP3A4:416 Pro>Leu, CYP3A4:P416L, c.1247C>T, g.105004C>T, g.158024C>T, g.27139C>T, g.37392513G>A, p.Pro416Leu |
G > A
|
Missense |
Pro416Leu
|
||
| rs4986910 | 1334 C allele, 445Thr allele, CYP3A4*3, CYP3A4:M445T, c.1334T>C, g.106150T>C, g.159170T>C, g.28285T>C, g.37391367A>G, mRNA 1438T>C, p.Met445Thr |
A > G
|
Missense |
Met445Thr
|
||
| rs4986913 | CYP3A4*19, CYP3A4:1503 C>T, CYP3A4:467 Pro>Ser, CYP3A4:P467S, c.1399C>T, g.106215C>T, g.159235C>T, g.28350C>T, g.37391302G>A, p.Pro467Ser |
G > A
|
Missense |
Pro467Ser
|
||
| rs4987161 | CYP3A4*17, CYP3A4:189 Phe>Ser, CYP3A4:670 T>C, CYP3A4:F189S, c.566T>C, g.151613T>C, g.20728T>C, g.37398924A>G, g.98593T>C, p.Phe189Ser |
A > G
|
Missense |
Phe189Ser
|
||
| rs776746 | CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, c.219-237G>A, c.321-1G>A, c.581-237G>A, c.689-1G>A, g.12083G>A, g.194135G>A, g.247167G>A, g.37303382C>T, g.6986A>G, intron 3 splicing defect, rs776746 A>G |
C > T
|
Not Available |
Overview
| Alternate Names: | cytochrome P450, subfamily IIIA (niphedipine oxidase) |
|---|---|
| Alternate Symbols: | CYP3 |
| PharmGKB Accession Id: | PA27114 |
Details
| Cytogenetic Location: | chr7 : q22.1 - q22.1 |
|---|---|
| GP mRNA Boundary†: | chr7 : 99245817 - 99464173 |
| GP Gene Boundary†: | chr7 : 99242817 - 99474173 |
| Strand: | minus |
| Product Name: | No data available |
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
-
Estrogen Metabolism Pathway
Estrogen metabolism in the liver.
External Pathways
Links to non-PharmGKB pathways.
Curated Information ?
| Evidence | Drug Class |
|---|---|
| antineoplastic agents |